The total number of records retrieved from this search are 148. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_606	Virus nameAdenovirus	Virus strainCRAd-CCL21-IL15	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeIL-15	Source of cell lineKey Laboratory of Zoonosis, Jilin University	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result70% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27380620
IDOV_609	Virus nameAdenovirus	Virus strainCRAd-CCL21-IL15	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeIL-15	Source of cell lineKey Laboratory of Zoonosis, Jilin University	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result40% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27380620
IDOV_612	Virus nameAdenovirus	Virus strainCRAd-CCL21-IL15	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeIL-15	Source of cell lineKey Laboratory of Zoonosis, Jilin University	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result18% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27380620
IDOV_615	Virus nameAdenovirus	Virus strainCRAd-CCL21-IL15	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeIL-15	Source of cell lineKey Laboratory of Zoonosis, Jilin University	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result10% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27380620
IDOV_717	Virus nameAvian influenza A virus	Virus strainH7N3 NS1-77	Virus genome typeRNA	Virus familyOrthomyxoviridae	Virus genome modificationMutations were introduced within the IAV NS1 gene to create a truncated protein of 77 aa (NS1-77)	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell lineNA	In-vitro toxicityNA	AssayImmunoassay detection	In-vitro virus concentration0.001 MOI	In-vitro result130% cancer cell death (calculated as relative to mock-infected)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectUp-regulation of IFN-aplha	Clinical trialNA	PMID27417501
IDOV_721	Virus nameAvian influenza A virus	Virus strainH7N3	Virus genome typeRNA	Virus familyOrthomyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell lineNA	In-vitro toxicityNA	AssayImmunoassay detection	In-vitro virus concentration0.001 MOI	In-vitro result148% cancer cell death (calculated as relative to mock-infected)	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectUp-regulation of IFN-aplha	Clinical trialNA	PMID27417501
IDOV_898	Virus nameHerpes simplex virus	Virus strainBaco-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNon- fusogenic ligated with EGFP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.01 pfu/cell	In-vitro result2% cancer cell killing after 24 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_899	Virus nameHerpes simplex virus	Virus strainSynco-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationFusogenic membrane ligated with GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.01 pfu/cell	In-vitro result20% cancer cell killing after 24 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_900	Virus nameHerpes simplex virus	Virus strainSynco-2D	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDouble fusogenic expressing EGFP and GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.01 pfu/cell	In-vitro result50% cancer cell killing after 24 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_901	Virus nameHerpes simplex virus	Virus strainBaco-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNon- fusogenic ligated with EGFP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.01 pfu/cell	In-vitro result20% cancer cell killing after 48 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_902	Virus nameHerpes simplex virus	Virus strainSynco-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationFusogenic membrane ligated with GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.01 pfu/cell	In-vitro result40% cancer cell killing after 48 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_903	Virus nameHerpes simplex virus	Virus strainSynco-2D	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDouble fusogenic expressing EGFP and GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.01 pfu/cell	In-vitro result80% cancer cell killing after 48 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_904	Virus nameHerpes simplex virus	Virus strainBaco-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNon- fusogenic ligated with EGFP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.01 pfu/cell	In-vitro result60% cancer cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_905	Virus nameHerpes simplex virus	Virus strainSynco-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationFusogenic membrane ligated with GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.01 pfu/cell	In-vitro result80% cancer cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_906	Virus nameHerpes simplex virus	Virus strainSynco-2D	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDouble fusogenic expressing EGFP and GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.01 pfu/cell	In-vitro result90% cancer cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_907	Virus nameHerpes simplex virus	Virus strainBaco-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNon- fusogenic ligated with EGFP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.1 pfu/cell	In-vitro result20% cancer cell killing after 24 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_908	Virus nameHerpes simplex virus	Virus strainSynco-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationFusogenic membrane ligated with GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.1 pfu/cell	In-vitro result30% cancer cell killing after 24 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_909	Virus nameHerpes simplex virus	Virus strainSynco-2D	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDouble fusogenic expressing EGFP and GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.1 pfu/cell	In-vitro result50% cancer cell killing after 24 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_910	Virus nameHerpes simplex virus	Virus strainBaco-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNon- fusogenic ligated with EGFP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.1 pfu/cell	In-vitro result50% cancer cell killing after 48 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_911	Virus nameHerpes simplex virus	Virus strainSynco-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationFusogenic membrane ligated with GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.1 pfu/cell	In-vitro result60% cancer cell killing after 48 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_912	Virus nameHerpes simplex virus	Virus strainSynco-2D	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDouble fusogenic expressing EGFP and GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.1 pfu/cell	In-vitro result100% cancer cell killing after 48 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_913	Virus nameHerpes simplex virus	Virus strainBaco-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNon- fusogenic ligated with EGFP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.1 pfu/cell	In-vitro result60% cancer cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_914	Virus nameHerpes simplex virus	Virus strainSynco-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationFusogenic membrane ligated with GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.1 pfu/cell	In-vitro result80% cancer cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_915	Virus nameHerpes simplex virus	Virus strainSynco-2D	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDouble fusogenic expressing EGFP and GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.1 pfu/cell	In-vitro result100% cancer cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_1261	Virus nameAdenovirus	Virus strainAxdAdb-3	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDouble mutated for E1A and E1B gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3	Concentration of cell line3.0E+3 cells per well	In-vitro toxicity	AssayMTT assay	In-vitro virus concentration30 MOI	In-vitro resultSurviving cell number reached to 10000	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18063085
IDOV_1290	Virus nameAdenovirus	Virus strainOBP-301	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit by Roche Diagnostics	In-vitro virus concentration0.1 MOI	In-vitro result98% cell viability after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18274558
IDOV_1291	Virus nameAdenovirus	Virus strainOBP-301	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit by Roche Diagnostics	In-vitro virus concentration0.1 MOI	In-vitro result90% cell viability after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18274558
IDOV_1292	Virus nameAdenovirus	Virus strainOBP-301	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit by Roche Diagnostics	In-vitro virus concentration0.1 MOI	In-vitro result100% cell viability after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18274558
IDOV_1293	Virus nameAdenovirus	Virus strainOBP-301	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit by Roche Diagnostics	In-vitro virus concentration0.1 MOI	In-vitro result98% cell viability after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18274558
IDOV_1294	Virus nameAdenovirus	Virus strainOBP-301	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit by Roche Diagnostics	In-vitro virus concentration1 MOI	In-vitro result98% cell viability after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18274558
IDOV_1295	Virus nameAdenovirus	Virus strainOBP-301	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit by Roche Diagnostics	In-vitro virus concentration1 MOI	In-vitro result80% cell viability after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18274558
IDOV_1296	Virus nameAdenovirus	Virus strainOBP-301	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit by Roche Diagnostics	In-vitro virus concentration1 MOI	In-vitro result70% cell viability after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18274558
IDOV_1297	Virus nameAdenovirus	Virus strainOBP-301	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit by Roche Diagnostics	In-vitro virus concentration1 MOI	In-vitro result60% cell viability after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18274558
IDOV_1298	Virus nameAdenovirus	Virus strainOBP-301	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit by Roche Diagnostics	In-vitro virus concentration10 MOI	In-vitro result60% cell viability after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18274558
IDOV_1299	Virus nameAdenovirus	Virus strainOBP-301	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit by Roche Diagnostics	In-vitro virus concentration10 MOI	In-vitro result40% cell viability after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18274558
IDOV_1300	Virus nameAdenovirus	Virus strainOBP-301	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit by Roche Diagnostics	In-vitro virus concentration10 MOI	In-vitro result30% cell viability afterd ay 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18274558
IDOV_1301	Virus nameAdenovirus	Virus strainOBP-301	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayCell proliferation kit by Roche Diagnostics	In-vitro virus concentration10 MOI	In-vitro result20% cell viability after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18274558
IDOV_1408	Virus nameParovirus	Virus strainH-1PV	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with norfloxacin (25 microgram/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result70% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19301953
IDOV_1409	Virus nameParovirus	Virus strainH-1PV	Virus genome typeDNA	Virus familyParoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with norfloxacin (25 microgram/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result30% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19301953
IDOV_2014	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.1 MOI	In-vitro result70% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2015	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 MOI	In-vitro result30% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2016	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration10 MOI	In-vitro result10% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2017	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2026	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with Docetaxel (7.5 nM)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.125 MOI	In-vitro result80% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2027	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with Docetaxel (15 nM)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.25 MOI	In-vitro result70% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2028	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with Docetaxel (30 nM)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration0.5 MOI	In-vitro result60% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2029	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with Docetaxel (60 nM)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 MOI	In-vitro result50% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2030	Virus nameReovirus	Virus strainReovirus T3D	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with Docetaxel (120 nM)	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration2 MOI	In-vitro result40% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus cause increase in apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21645351
IDOV_2278	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result60% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2292	Virus nameVesicular stomatitis virus	Virus strainVSV-Delta-M51-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationDeletion of M51 gene and insertion of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result80% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2306	Virus nameVesicular stomatitis virus	Virus strainVSV-p1-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationInsertion of P gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result70% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2320	Virus nameVesicular stomatitis virus	Virus strainSev-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationInsertion of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2334	Virus nameVesicular stomatitis virus	Virus strainRSV-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationInsertion of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2348	Virus nameVesicular stomatitis virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2362	Virus nameVesicular stomatitis virus	Virus strainVSV-Delta-M51-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationDeletion of M51 gene and insertion of GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2376	Virus nameVesicular stomatitis virus	Virus strainVSV-p1-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationInsertion of P gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2390	Virus nameVesicular stomatitis virus	Virus strainSev-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_2404	Virus nameVesicular stomatitis virus	Virus strainRSV-GFP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing GFP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell linePancreatic ductal adeonocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line80% confluent monolayer	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectDownregulation of IFN-Gamma	Clinical trialNA	PMID22238308
IDOV_3404	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.001 MOI	In-vitro resultNo cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3405	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.005 MOI	In-vitro resultNo cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3406	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.01 MOI	In-vitro resultNo cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3407	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.05 MOI	In-vitro result35% cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3408	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.1 MOI	In-vitro result30% cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3424	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (2 × 10⁻² micromolar) after 1 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.01 MOI	In-vitro result75% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3425	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (2 × 10⁻² micromolar) after 24 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.01 MOI	In-vitro result75% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3432	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (1 × 10⁻² micromolar) after 1 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.01 MOI	In-vitro result25% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3433	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (1 × 10⁻² micromolar) after 24 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.01 MOI	In-vitro result50% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3440	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (5 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.01 MOI	In-vitro result70% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3441	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (5 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.03 MOI	In-vitro result60% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3442	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (5 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssaySRB assay	In-vitro virus concentration0.05 MOI	In-vitro result52% of the tumor cell mass remain after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3443	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (5 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssayCTB assay	In-vitro virus concentration0.01 MOI	In-vitro result50% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3444	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (5 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssayCTB assay	In-vitro virus concentration0.03 MOI	In-vitro result40% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3445	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of three gene beta-glucouronidase, galactosidase and GFP	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with nab-palcitaxel (2.5 nM)and gemcitabine (5 nM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic adenocarcinoma cell line	Cell lineBxPC-3	Concentration of cell line4.0E+4 cells per well	In-vitro toxicityNA	AssayCTB assay	In-vitro virus concentration0.05 MOI	In-vitro result30% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28607950
IDOV_3538	Virus nameAdenovirus	Virus strainAdenovirus ZD55	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion in E1B55 viral protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result90% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID28880012
IDOV_3539	Virus nameAdenovirus	Virus strainAdenovirus ZD55	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion in E1B55 viral protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result80% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID28880012
IDOV_3540	Virus nameAdenovirus	Virus strainAdenovirus ZD55	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion in E1B55 viral protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result70% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID28880012
IDOV_3541	Virus nameAdenovirus	Virus strainAdenovirus ZD55	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion in E1B55 viral protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration20 MOI	In-vitro result58% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID28880012
IDOV_3542	Virus nameAdenovirus	Virus strainAdenovirus GD55	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationGOLPH2 regulated aoncolytic adenovirus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result70% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID28880012
IDOV_3543	Virus nameAdenovirus	Virus strainAdenovirus GD55	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationGOLPH2 regulated aoncolytic adenovirus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result50% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID28880012
IDOV_3544	Virus nameAdenovirus	Virus strainAdenovirus GD55	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationGOLPH2 regulated aoncolytic adenovirus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result40% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID28880012
IDOV_3545	Virus nameAdenovirus	Virus strainAdenovirus GD55	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationGOLPH2 regulated aoncolytic adenovirus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration20 MOI	In-vitro result30% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID28880012
IDOV_3619	Virus nameMeasles virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result60% cell viability after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3620	Virus nameMeasles virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result20% cell viability after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3633	Virus nameMumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result60% cell viability after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3634	Virus nameMumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result10% cell viability after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3647	Virus nameMeasles and mumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationMeasles virus in combination with mumps virus	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result30% cell viability after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3648	Virus nameMeasles and mumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationMeasles virus in combination with mumps virus	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result12% cell viability after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3723	Virus nameVesicular stomatitis virus	Virus strainVSV-GP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationvirus expressing GP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell lineNA	In-vitro toxicityNA	AssayAbsorbance measurements	In-vitro virus concentration0.1 MOI	In-vitro result15% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryVirus induce apoptosis in cancer cell	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID29696636
IDOV_3724	Virus nameVesicular stomatitis virus	Virus strainVSV-GP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationvirus expressing GP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M-Luc	Concentration of cell lineNA	In-vitro toxicityNA	AssayAbsorbance measurements	In-vitro virus concentration0.1 MOI	In-vitro result50% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryVirus induce apoptosis in cancer cell	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID29696636
IDOV_3730	Virus nameVesicular stomatitis virus	Virus strainVSV-GP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationvirus expressing GP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell lineNA	In-vitro toxicityNA	AssayAbsorbance measurements	In-vitro virus concentration10 MOI	In-vitro result15% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryVirus induce apoptosis in cancer cell	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID29696636
IDOV_3731	Virus nameVesicular stomatitis virus	Virus strainVSV-GP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationvirus expressing GP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M-Luc	Concentration of cell lineNA	In-vitro toxicityNA	AssayAbsorbance measurements	In-vitro virus concentration10 MOI	In-vitro result18% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryVirus induce apoptosis in cancer cell	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID29696636
IDOV_3753	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.0001 MOI	In-vitro result100% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3754	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result100% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3755	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result98% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3756	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result20% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3757	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 MOI	In-vitro result100% cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3758	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration3 MOI	In-vitro result100% cell killing after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3767	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result60% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3768	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result50% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3769	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (5 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result40% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_3770	Virus nameVaccinia virus	Virus strainvv-smac	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of smac and gpt gene in TK	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with gemcitabine (5 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of china	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line5.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro result30% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID30365143
IDOV_4126	Virus nameAdenovirus	Virus strainAduPARE1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of E1A gene upstream of uPAR promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drug Gemcitabine (0.01 ng/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 vp/cell	In-vitro result80% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26227809
IDOV_4127	Virus nameAdenovirus	Virus strainAduPARE1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of E1A gene upstream of uPAR promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drug Gemcitabine (1 ng/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1000 vp/cell	In-vitro result50% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26227809
IDOV_4128	Virus nameAdenovirus	Virus strainAduPARE1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of E1A gene upstream of uPAR promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drug Gemcitabine (10 ng/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10000 vp/cell	In-vitro result20% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26227809
IDOV_4129	Virus nameAdenovirus	Virus strainAduPARE1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of E1A gene upstream of uPAR promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drug Gemcitabine (100 ng/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100000 vp/cell	In-vitro result100% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26227809
IDOV_4130	Virus nameAdenovirus	Virus strainAduPARE1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of E1A gene upstream of uPAR promoter	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drug Gemcitabine (1000 ng/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1000000 vp/cell	In-vitro result100% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26227809
IDOV_4131	Virus nameAdenovirus	Virus strainAduPARE1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of E1A gene upstream of uPAR promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 vp/cell	In-vitro result100% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26227809
IDOV_4132	Virus nameAdenovirus	Virus strainAduPARE1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of E1A gene upstream of uPAR promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1000 vp/cell	In-vitro result85% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26227809
IDOV_4133	Virus nameAdenovirus	Virus strainAduPARE1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of E1A gene upstream of uPAR promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10000 vp/cell	In-vitro result35% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26227809
IDOV_4134	Virus nameAdenovirus	Virus strainAduPARE1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of E1A gene upstream of uPAR promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100000 vp/cell	In-vitro result20% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26227809
IDOV_4135	Virus nameAdenovirus	Virus strainAduPARE1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of E1A gene upstream of uPAR promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1000000 vp/cell	In-vitro result100% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectNA	Clinical trialNA	PMID26227809
IDOV_4308	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate adenocarcinoma	Cell linePC-3	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 pfu	In-vitro result72.7 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4330	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreas adenocarcinoma	Cell lineBxPC-3	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 pfu	In-vitro result98.8 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4909	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJilin University china	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4910	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJilin University china	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4911	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJilin University china	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result100% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4912	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJilin University china	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result100% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4913	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 gene	Source of cell lineJilin University china	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4914	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 gene	Source of cell lineJilin University china	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result90% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4915	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 gene	Source of cell lineJilin University china	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result30% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4916	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 gene	Source of cell lineJilin University china	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result15% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4917	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 and CCL21gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 and CCL21 gene	Source of cell lineJilin University china	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result70% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4918	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 and CCL21gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 and CCL21 gene	Source of cell lineJilin University china	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result40% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4919	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 and CCL21gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 and CCL21 gene	Source of cell lineJilin University china	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result15% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4920	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 and CCL21gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 and CCL21 gene	Source of cell lineJilin University china	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result15% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_5065	Virus nameAvian orthoreovirus	Virus strainARV-PB1	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman pancreatic cancer cell line	Cell linePC-3	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro result80% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectInduction of Interferon related gene expression	Clinical trialNA	PMID28441762
IDOV_5072	Virus nameAdenovirus	Virus strainZD-55-TRAIl-IETD-smac	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of TRAIL and smac gene via IETD linker	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectInduction of Interferon related gene expression	Clinical trialNA	PMID28440486
IDOV_5073	Virus nameAdenovirus	Virus strainZD-55-TRAIl-IETD-smac	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of TRAIL and smac gene via IETD linker	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 MOI	In-vitro result98% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectInduction of Interferon related gene expression	Clinical trialNA	PMID28440486
IDOV_5074	Virus nameAdenovirus	Virus strainZD-55-TRAIl-IETD-smac	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of TRAIL and smac gene via IETD linker	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration4 MOI	In-vitro result70% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectInduction of Interferon related gene expression	Clinical trialNA	PMID28440486
IDOV_5075	Virus nameAdenovirus	Virus strainZD-55-TRAIl-IETD-smac	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of TRAIL and smac gene via IETD linker	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 MOI	In-vitro result60% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectInduction of Interferon related gene expression	Clinical trialNA	PMID28440486
IDOV_5076	Virus nameAdenovirus	Virus strainZD-55-TRAIl-IETD-smac	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of TRAIL and smac gene via IETD linker	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 MOI	In-vitro result55% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectInduction of Interferon related gene expression	Clinical trialNA	PMID28440486
IDOV_5077	Virus nameAdenovirus	Virus strainZD-55-TRAIl-IETD-smac	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of TRAIL and smac gene via IETD linker	Virus aloneYes	Virus in combination with drug/radiationVirus in combination with SNS032 5ng/ml	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result55% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectInduction of Interferon related gene expression	Clinical trialNA	PMID28440486
IDOV_5078	Virus nameAdenovirus	Virus strainZD-55-TRAIl-IETD-smac	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of TRAIL and smac gene via IETD linker	Virus aloneYes	Virus in combination with drug/radiationVirus in combination with SNS032 10ng/ml	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 MOI	In-vitro result45% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectInduction of Interferon related gene expression	Clinical trialNA	PMID28440486
IDOV_5079	Virus nameAdenovirus	Virus strainZD-55-TRAIl-IETD-smac	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of TRAIL and smac gene via IETD linker	Virus aloneYes	Virus in combination with drug/radiationVirus in combination with SNS032 20ng/ml	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration4 MOI	In-vitro result30% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectInduction of Interferon related gene expression	Clinical trialNA	PMID28440486
IDOV_5080	Virus nameAdenovirus	Virus strainZD-55-TRAIl-IETD-smac	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of TRAIL and smac gene via IETD linker	Virus aloneYes	Virus in combination with drug/radiationVirus in combination with SNS032 40ng/ml	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 MOI	In-vitro result20% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectInduction of Interferon related gene expression	Clinical trialNA	PMID28440486
IDOV_5081	Virus nameAdenovirus	Virus strainZD-55-TRAIl-IETD-smac	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of TRAIL and smac gene via IETD linker	Virus aloneYes	Virus in combination with drug/radiationVirus in combination with SNS032 80ng/ml	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineShanghai cell collection	Origin of cell lineHuman pancreatic cancer cell line	Cell lineBxPC-3	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 MOI	In-vitro result10% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectInduction of Interferon related gene expression	Clinical trialNA	PMID28440486
IDOV_5559	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman pancreatic cell line	Cell lineBxPC-3	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1 MOI	In-vitro resultSignificant death of cancer cell line after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectNA	Clinical trialNA	PMIDUS7270812B2
IDOV_5564	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman pancreatic cell line	Cell lineBxPC-3	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1 MOI	In-vitro resultSignificant death of cancer cell line after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectNA	Clinical trialNA	PMIDUS7270812B2
IDOV_5569	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationSindbis virus in combination with Reovirus	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman pancreatic cell line	Cell lineBxPC-3	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayNA	In-vitro virus concentration1 MOI	In-vitro resultEnhancer cytolytic effect in combination after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectNA	Clinical trialNA	PMIDUS7270812B2
IDOV_5575	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman pancreatic cell line	Cell lineBxPC-3	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismNude mice xenografted subcutaneously for BxPC3	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to below 2.0 cm after 10 weeks	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectNA	Clinical trialNA	PMIDUS7270812B2
IDOV_5576	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman pancreatic cell line	Cell lineBxPC-3	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismNude mice xenografted subcutaneously for BxPC3	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to below 3.0 cm after 10 weeks	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectNA	Clinical trialNA	PMIDUS7270812B2
IDOV_5577	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationSindbis virus in combination with Reovirus	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman pancreatic cell line	Cell lineBxPC-3	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismNude mice xenografted subcutaneously for BxPC3	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor volume after 10 weeks	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectNA	Clinical trialNA	PMIDUS7270812B2
IDOV_5578	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman pancreatic cell line	Cell lineBxPC-3	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismNude mice xenografted subcutaneously for MIAPaCa-2	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to below 5.0 cm after 12 weeks	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectNA	Clinical trialNA	PMIDUS7270812B2
IDOV_5579	Virus nameReovirus	Virus strainwild type	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman pancreatic cell line	Cell lineBxPC-3	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismNude mice xenografted subcutaneously for MIAPaCa-2	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor volume reduced to below 4.0 cm after 12 weeks	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectNA	Clinical trialNA	PMIDUS7270812B2
IDOV_5623	Virus nameNewcastle disease virus	Virus strainNDV-MK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell line80% confluency	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration3×10³ pfu	In-vitro result50% of cancer cell death occurs	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis by virus infection	Immunogenic effectInduction of IFN-Gamma production	Clinical trialNA	PMIDUS7470426
IDOV_5843	Virus nameNewcastle disease virus	Virus strainNDV-PPMK107	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman prostae carcinoma cell line	Cell linePC-3	Concentration of cell line80% confluency	In-vitro toxicityNA	AssayNA	In-vitro virus concentration3.1 ×10³ pfu	In-vitro result50% cancer cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS8105578
IDOV_5888	Virus nameRespiratory synctial virus	Virus strainMutant	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 MOI	In-vitro result20% cell survived after treatment	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMIDUS9241998
IDOV_5893	Virus nameAdenovirus	Virus strainCGTG-602	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus E1A promoter is replaced by human E2F1 promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3-MM2	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 ×10⁴ pfu	In-vitro resultAll cell death occurs after 100 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS9410129